A Third View: Discussing acoramidis and part B of the ATTRibute trial in ATTR-CM (Transthyretin Amyloid Cardiomyopathy)Ticker(s): BBIO, PFE, ALNY
- Director of Cardiac Amyloidosis & Cardiac Transplantation program and Associate Professor, Medicine-Cardiology at the University of Colorado.
- Currently manages ~60 active ATTR cardiac amyloid patients and has prescribed Tafamidis.
- Research focuses on Cardiac Amyloidosis, Advanced Heart Failure, Cardiac Transplantation, and Mechanical Circulatory Support / Ventricular Assist Devices; has participated in multiple clinical trials investigating new pharmacologic and device therapies for patients with advanced heart failure and cardiac amyloidosis.
why do you think Part A of ATTRibute failed?Added By: wilson_admin
What do you think of the Part B probability of success?Added By: wilson_admin
How do you view acoramidis compared to other optionsAdded By: wilson_admin
Thinking of the three entrants into the CM arena - vutrisiran, eplontersen, and acoramidis, characterize what you believe are the differentiating advantages/disadvantages of each?Added By: wilson_admin
Describe how you see the marketing shaking out with the emergence of three different players with three different solutions (vutrisiran, eplontersen, and acoramidis) in the aTTR-CM market? Are there unique patient types for each?
What do you think the win ratio will be for ATTRibute-CM?Added By: wilson_admin
In ATTR-ACT, the greatest benefit seemed to be in NYHA 1-2 irrespective of wt or m — that suggests that earlier disease responds better. Since the hypothesis is that ATTRibute-CM has a left-shifted population, should we expect a higher win ratio with AG10?Added By: wilson_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.